High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19

Status Withdrawn

Clinical Trial Summary

COVID-19 pandemic has spread all over the world, and hospitalization of the patients with COVİD-19 Pneumonia has become a great burden to the Intensive Care Units. Unfortunately there is still no curative method for the disease yet. Intensive Care Units provide general care for the patients; including oxygen therapy, maintenance of the organ systems (e.g., cardiovascular, renal), nutrition, antibiotic therapy for secondary infections, and etc. One of the major problems in COVID-19 is macrophage activation syndrome, also known as cytokine storm. It stems from exaggerated inflammatory response, which causes increased cytokine release and results in clinical deterioration of the patients. Many drugs have been used to prevent this exaggerated inflammation, like corticosteroids, interleukin (IL) receptor blockers, plasma exchange, etc. In this study our aim is to investigate the effectiveness of high dose corticosteroid (methylprednisolone 250 mg for 3 days) and an IL-6 receptor antagonist (tocilizumab) in the treatment of the cytokine storm of the COVID-19 patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05133635
Study type	Interventional
Source	Marmara University
Contact
Status	Withdrawn
Phase	Phase 4
Start date	February 1, 2021
Completion date	April 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03685383` - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation	N/A
Recruiting	`NCT05491304` - Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis	Phase 4
Completed	`NCT05307601` - Immune Response Following COVID-19 in Hemodialysis Patients
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Completed	`NCT04476745` - The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People	N/A
Completed	`NCT04798677` - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine	N/A
Completed	`NCT01302223` - Keratinocyte Growth Factor and Cytokines in Burns.	N/A
Completed	`NCT04483271` - The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm	N/A
Not yet recruiting	`NCT05013034` - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients	Phase 2
Completed	`NCT04910893` - Cytokine Adsorption in Severe, Refractory Septic Shock	N/A
Completed	`NCT04854252` - Inflammatory Response to Opioid Versus Opioid Free Anesthesia	N/A
Completed	`NCT04366908` - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome	Phase 2
Terminated	`NCT04415073` - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19	Phase 2
Completed	`NCT04377308` - Fluoxetine to Reduce Intubation and Death After COVID19 Infection	Phase 4
Completed	`NCT04324528` - Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Completed	`NCT05476848` - Relationship Between Oral Findings and Salivary Factors in Sars-Cov-2 Patients	N/A
Completed	`NCT04913298` - Prospective Study for the Application of Cytosorb® in Critically Ill Patients	N/A
Recruiting	`NCT04753476` - Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia	Phase 2
Terminated	`NCT04327505` - Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19	Phase 2/Phase 3
Withdrawn	`NCT04433078` - RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM	Phase 2